Limits...
Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (BiofermenticsTM).

Shin R, Suzuki M, Mizutani T, Susa N - Evid Based Complement Alternat Med (2007)

Bottom Line: In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF.Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group.These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

View Article: PubMed Central - PubMed

Affiliation: Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 Japan. rshin@ciala.co.jp.

ABSTRACT
The effects of lactic acid bacteria-fermented soybean extract (Biofermentics; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K(2)Cr(2)O(7)) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

No MeSH data available.


Related in: MedlinePlus

Effects of oral BF administration on serum AST activity in rats with d-galactosamine (GMN)-induced hepatic disorders. The control group (open square) was given MF powdery feed only for 3 weeks, while the BF group (filled circle) was given MF powdery feed containing 5% BF. On the first day of the fourth week of feeding period, the rats of both groups were injected intraperitoneally with GMN solution (500 mg/kg body wt). Serum AST was measured on days 1, 2, 3 and 6 after GMN injection. Values indicate mean ± SD (n = 7). *P < 0.05 against the respective control values. BF, Biofermentics™ (lactic acid bacteria-fermented soybean extract).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2722200&req=5

Figure 2: Effects of oral BF administration on serum AST activity in rats with d-galactosamine (GMN)-induced hepatic disorders. The control group (open square) was given MF powdery feed only for 3 weeks, while the BF group (filled circle) was given MF powdery feed containing 5% BF. On the first day of the fourth week of feeding period, the rats of both groups were injected intraperitoneally with GMN solution (500 mg/kg body wt). Serum AST was measured on days 1, 2, 3 and 6 after GMN injection. Values indicate mean ± SD (n = 7). *P < 0.05 against the respective control values. BF, Biofermentics™ (lactic acid bacteria-fermented soybean extract).

Mentions: As shown in Fig. 2, serum AST activity in the control group increased sharply to 3172 ± 2379 IU/l on day 1 and 2811 ± 2210 IU/l on day 2, then decreased sharply to 372 ± 323 IU/l on day 3 after injection of GMN. In the BF group, AST was significantly (P < 0.05) lowered to 1423 ± 1857, 1009 ± 1395 and 142 ± 161 IU/l on those days, respectively, that is, to ∼45% the level of values in the control group.Figure 2.


Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (BiofermenticsTM).

Shin R, Suzuki M, Mizutani T, Susa N - Evid Based Complement Alternat Med (2007)

Effects of oral BF administration on serum AST activity in rats with d-galactosamine (GMN)-induced hepatic disorders. The control group (open square) was given MF powdery feed only for 3 weeks, while the BF group (filled circle) was given MF powdery feed containing 5% BF. On the first day of the fourth week of feeding period, the rats of both groups were injected intraperitoneally with GMN solution (500 mg/kg body wt). Serum AST was measured on days 1, 2, 3 and 6 after GMN injection. Values indicate mean ± SD (n = 7). *P < 0.05 against the respective control values. BF, Biofermentics™ (lactic acid bacteria-fermented soybean extract).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2722200&req=5

Figure 2: Effects of oral BF administration on serum AST activity in rats with d-galactosamine (GMN)-induced hepatic disorders. The control group (open square) was given MF powdery feed only for 3 weeks, while the BF group (filled circle) was given MF powdery feed containing 5% BF. On the first day of the fourth week of feeding period, the rats of both groups were injected intraperitoneally with GMN solution (500 mg/kg body wt). Serum AST was measured on days 1, 2, 3 and 6 after GMN injection. Values indicate mean ± SD (n = 7). *P < 0.05 against the respective control values. BF, Biofermentics™ (lactic acid bacteria-fermented soybean extract).
Mentions: As shown in Fig. 2, serum AST activity in the control group increased sharply to 3172 ± 2379 IU/l on day 1 and 2811 ± 2210 IU/l on day 2, then decreased sharply to 372 ± 323 IU/l on day 3 after injection of GMN. In the BF group, AST was significantly (P < 0.05) lowered to 1423 ± 1857, 1009 ± 1395 and 142 ± 161 IU/l on those days, respectively, that is, to ∼45% the level of values in the control group.Figure 2.

Bottom Line: In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF.Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group.These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

View Article: PubMed Central - PubMed

Affiliation: Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 Japan. rshin@ciala.co.jp.

ABSTRACT
The effects of lactic acid bacteria-fermented soybean extract (Biofermentics; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of d-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K(2)Cr(2)O(7)) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

No MeSH data available.


Related in: MedlinePlus